Cleanroom wipes to see improvements

Expect more features that promote ease of use and protect against cross-contamination in that intrepid soldier of drug production, the wipe. Manufacturers are also executing on promises of environmental preservation by developing products that are biodegradable, for example.

Features under development are task-specific, says market researcher Freedonia Group, in a $4,900 report published last month. Manufacturing and healthcare wipes remain the largest segments within the industrial wipes market. Cleanroom and surface-preparation wipes are expected to be leading subsegments.

Freedonia projects the overall U.S. wipes market to grow at a compound rate of 4.3 percent through 2014, to $2.3 billion. The industrial segment CAGR alone is projected at 4.7 percent, to $1 billion--58 billion units.

- here's the Freedonia release

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.